MiNK Therapeutics to Present Updated Clinical Data of allo-iNKT Cell Therapy in Solid Tumors at AACR Annual Meeting

Rhea-AI Summary

MiNK Therapeutics, Inc. (NASDAQ: INKT) announced an upcoming presentation of updated clinical data on its allo-iNKT cell therapy, agenT-797, scheduled for the American Association for Cancer Research (AACR) Annual Meeting from April 14-19, 2023. The presentation, titled 'Phase 1 clinical update of allogeneic invariant natural killer T cells (iNKTs),' will be conducted by Dr. Benedito Carneiro on April 18, 2023. MiNK is focused on developing innovative iNKT cell therapies for cancer treatment, leveraging a scalable manufacturing platform. This update could impact investor sentiment based on the therapy's progress in advanced solid tumors.

Positive

• Upcoming presentation of clinical data at AACR Annual Meeting, potentially boosting investor interest.
• Focus on next-generation iNKT therapies advancing towards clinical applications.

Negative

• None.

– Clinical update of allo-iNKT cells (agenT-797) alone or in combination with approved anti-PD-1 in advanced solid tumors

NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced plans to present updated clinical data and development plans in solid tumors at the American Association for Cancer Research (AACR) Annual Meeting, April 14-19^th, 2023.

Presentation Details

Title: Phase 1 clinical update of allogeneic invariant natural killer T cells (iNKTs), agenT-797, alone or in combination with pembrolizumab or nivolumab in patients with advanced solid tumors

Abstract Number: CT275

Session Title: Phase I Clinical Trials 2

Session Date and Time: Tuesday April 18, 2023, 1:30 PM - 5:00 PM ET

Presenting Author: Dr. Benedito Carneiro

About MiNK Therapeutics

MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/. Follow us on Twitter @MiNK_iNKT.

Contact
Alexa Buffa
781-674-4428
communications@minktherapeutics.com

Investor relations:
Zack Armen
917-362-1370
investor@minktherapeutics.com

FAQ

What is MiNK Therapeutics focusing on with its allo-iNKT cell therapy, agenT-797?

MiNK Therapeutics is focused on the clinical development of its allo-iNKT cell therapy, agenT-797, for treating advanced solid tumors.

When is the presentation of updated clinical data for agenT-797?

The updated clinical data for agenT-797 will be presented on April 18, 2023, at the AACR Annual Meeting.

Who will present the clinical update for MiNK Therapeutics at the AACR Meeting?

Dr. Benedito Carneiro will present the clinical update for MiNK Therapeutics at the AACR Meeting.

What is the significance of the AACR Annual Meeting for MiNK Therapeutics?

The AACR Annual Meeting provides MiNK Therapeutics an opportunity to share advancements and data on its iNKT cell therapies, influencing investor perception.